Purple Biotech stock falls amid interim phase 1 data of NT219 in advanced tumors
seekingalpha.com
finance
2022-05-27 13:00:53

Design Cells/iStock via Getty Images Purple Biotech (NASDAQ:PPBT) reported interim data from a phase 1 trial of NT219 as a standalone therapy to treat adults with advanced solid tumors. The study included patients with colorectal, pancreatic and breast cancers and also gastroesophageal junction (GEJ), esophageal and appendiceal cancers. Out of 12 evaluable patients, a confirmed partial response of more than 5.5 months was seen in a patient with GEJ cancer. Stable disease was seen in 3 out of 4 patients with mutated-KRAS colorectal cancer, according to the company's May 27 press release.
